Form 4: PLUS THERAPEUTICS CFO Buys 20,000 Shares

PLUS THERAPEUTICS CFO Andrew Sims acquired 20,000 shares of common stock at an average price of $0.51.

Summary

• Andrew John Hugh MacIntyre Sims, Chief Financial Officer of PLUS THERAPEUTICS, INC. (PSTV), acquired 20,000 shares of common stock.
• The transaction occurred on November 4, 2025, and was executed under a Rule 10b5-1 plan.
• The shares were purchased at a weighted average price of $0.51 per share, with prices ranging from $0.504 to $0.509.
• Following this transaction, Andrew Sims beneficially owns a total of 68,138 shares of common stock.

Sentiment

Score: 7

Explanation: The Chief Financial Officer's purchase of a significant number of shares indicates strong insider confidence in the company's future performance and valuation.

Positives

• Chief Financial Officer Andrew Sims purchased 20,000 shares of common stock, indicating strong insider confidence in the company's future prospects.
• The transaction was made pursuant to a Rule 10b5-1 plan, suggesting a pre-planned investment strategy rather than a reactive one.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders may interpret the CFO's stock purchase as a positive signal, potentially increasing confidence in the company's future performance and stock value.
• The transaction reinforces the alignment of interests between management and shareholders, as a key executive is increasing their personal stake in the company.

Key Dates

Recommendation

The Chief Financial Officer's decision to purchase a substantial block of shares at the current market price suggests a strong belief in the company's intrinsic value and future growth potential. This insider buying activity, especially from a key financial executive, often signals undervaluation or anticipated positive developments, making it a compelling 'buy' signal for investors.

Keywords

PLUS THERAPEUTICS, PSTV, Andrew Sims, CFO, Insider Trading, Stock Purchase, Form 4, Equity Acquisition, Rule 10b5-1